Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343077 · ClinicalTrials.gov registry record · Phase 2
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
A Phase 2 study of Prostate Cancer Patients on Active Surveillance, sponsored by Ashutosh Kumar Tewari.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT06343077 is a Phase 2 study of Prostate Cancer Patients on Active Surveillance that is actively recruiting participants, run by Ashutosh Kumar Tewari. The registered enrollment target is 114 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06343077, a Phase 2 study of Prostate Cancer Patients on Active Surveillance, is actively recruiting participants, sponsored by Ashutosh Kumar Tewari.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Conditions Studied
Interventions
- DRUG Poly-ICLC intramuscular (IM) injection
- DRUG Poly-ICLC, Intertumoral (IT) injection
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai (ISMMS) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06343077
The ClinicalTrials.gov registry entry for NCT06343077 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ashutosh Kumar Tewari, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer Patients on Active Surveillance appearing as the primary indexed condition, and to 2 interventions - of which Poly-ICLC intramuscular (IM) injection is the first listed.
NCT06343077 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06343077 about?
NCT06343077 is a clinical study titled "Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance". This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
What is the current status of trial NCT06343077?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2024-01-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06343077 study?
This clinical trial studies the following conditions: Prostate Cancer Patients on Active Surveillance.
What interventions are being tested in trial NCT06343077?
The interventions under investigation include: Poly-ICLC intramuscular (IM) injection (DRUG), Poly-ICLC, Intertumoral (IT) injection (DRUG).
Who is sponsoring clinical trial NCT06343077?
This trial is sponsored by Ashutosh Kumar Tewari, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343077 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.